Jefferson University Hospitals

Provider Profile

Serge Jabbour, MD, FACP, FACE

Jefferson University Physician

Academic Title: Professor
Division Director, Endocrinology
Director, Diabetes Center
Director, Comprehensive Weight Management Program

Specialties
Endocrinology/Diabetes & Metabolism
Endocrinology/Diabetes & Metabolism - Thyroid & Parathyroid
Endocrinology/Diabetes & Metabolism - Weight Management

Appointment Scheduling

Call 1-800-JEFF-NOW

Existing Patients

Jefferson Health MyChart

Log in to MyChart and schedule an appointment online.

New Patients  | Online Scheduling

New patients can use Online Scheduling to view available appointment times and schedule directly.

More Ways to Get in Touch

Call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
Walnut Towers, Suite 600
211 S. 9th Street
Philadelphia PA 19107
Phone: (215) 955-1925
Fax: (215) 928-3160

Medical Services

Years in Practice

19

Board Certifications

  • Internal Medicine
  • Endocrinology, Diabetes & Metabolism

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Philadelphia Magazine's Top Docs 2016,2015,2014,2013,2012,2011

Education

  • St. Joseph's University, Beirut, Lebanon, Medical School

Internship

  • Cooper Medical Center, Camden, NJ

Residency

  • Cooper Medical Center, Camden, NJ

Fellowship

  • Thomas Jefferson University Hospital

Recent Publications

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study

Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial

Durability of response to dapagliflozin: a review of long-term efficacy and safety

Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial

Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)

Evaluation and management of medullary thyroid cancer

Diagnosis and management of thyroid lymphoma

Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014

Insulin degludec 200 Units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 Units/mL in patients with type 2 diabetes requiring high-dose insulin

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Musculoskeletal manifestations of primary hyperparathyroidism

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

SGLT2 inhibitors

Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study

Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time

An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients

Incidence and Severity of Pancreatogenic Diabetes After Pancreatic Resection

Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study

SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem

Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?